Home  Welcoming remarks Plenaries & events Panels Advance day Exhibition Benefactors Organizers Info



Medical -




Protalix is a publicly traded clinical stage biopharmaceutical company

that is focused on developing and manufacturing of recombinant

therapeutic proteins. Protalix uses its proprietary plant cell culture and

bioreactor technology for the expression of recombinant therapeutic

proteins, and is currently developing several biopharmaceutical


Our patented plant cell contained bioreactor system enables the

expression of specific human genes, encoding expression for proteins

of pharmaceutical or therapeutic value. Subsequently, the expressed

protein of interest is extracted from the plant cells and purified to a

pharmaceutical grade.

Our lead product under development is prGCD, an enzyme for the

treatment of Gaucher disease. We completed a Phase I clinical

trial under FDA Investigational New Drug (IND) approval to assess

the safety of prGCD in healthy volunteers. All doses administered

to subjects in the Phase I clinical trial demonstrated a good safety


Protalix is currently running Phase III clinical trials in major medical

centers worldwide to assess the safety and efficacy of prGCD in

Gaucher disease patients.

Additionally, we have an innovative product pipeline, including various

proprietary therapeutic protein candidates, which will enable us to

progress to preclinical studies for additional products during 2008.

Protalix established a GMP bio-manufacturing plant and state-of-theart

research facility for the development and large-scale production of

clinical grade proteins in Israel.

Key Advantages of our ProCellEx expression system:

Enables penetration of patent protected markets.

Flexible polyethylene bioreactors entail very low initial capital investment.

Requires less costly hands-on maintenance.

Significant advantages over cell based mammalian systems




Watch movie >>

<< Back
Home Plenaries & events Panels Exhibition: “Tomorrow’s Spaces” Benefactors Info & schedule Conference Album Articles
Background Policy Papers prepared for the President's Conference

Powered by HAARETZ